Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy
Open Access
- 4 November 2026
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (11) , e015096
Abstract
No abstract availableFunding Information
- Ludwig Center at Harvard (n/a)
- Center for Cancer Research (R01CA236910)
- National Cancer Institute (K08CA248960)
- Mark Foundation For Cancer Research (ASPIRE award)
- Gene Lay Institute (n/a)
- National Institute of General Medical Sciences (T32-GM133364-01A1)
- National Institute of General Medical Sciences (T32GM007753)
- American Cancer Society (Research Scholar Grant PF-24-1316850-01-CD)
- Burroughs Wellcome Fund (CAMS)
This publication has 50 references indexed in Scilit:
- Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancerCancer Cell, 2025
- Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 studyThe Lancet Oncology, 2024
- A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanomaCell, 2024
- Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth In VivoACS Nano, 2022
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaCell, 2018
- Allele-Specific HLA Loss and Immune Escape in Lung Cancer EvolutionCell, 2017
- The two faces of IL-6 in the tumor microenvironmentSeminars in Immunology, 2014
- Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumorsCancer Immunology, Immunotherapy, 2011
- CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumorsCancer Immunology, Immunotherapy, 2008
- Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategyNature, 1986